This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.

Clinical trial NCT07102342 · RECRUITING

Trial details

NCT number: NCT07102342
Sponsor: iRegene Therapeutics Co., Ltd.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Parkinson Disease

Start date: 2026-01-12
Primary completion: 2027-09-01
Enrollment: 5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.